1. Field of the Invention
The invention relates generally to artificial heart pumps and, in particular, to an improved valve for reducing thrombus in ventricular assist devices.
2. Description of the Prior Art
The heart is the muscle that drives the cardiovascular system in living beings. Acting as a pump, the heart moves blood throughout the body to provide oxygen, nutrients, hormones, and to remove waste products. The blood follows two separate pathways in the human body, the so-called pulmonary and systemic circulatory circuits. In the pulmonary circuit, the heart pumps blood first to the lungs to release carbon dioxide and bind oxygen, and then back to the heart. Thus, oxygenated blood is constantly being supplied to the heart. In the systemic circuit, the longer of the two, the heart pumps oxygenated blood through the rest of the body to supply oxygen and remove carbon dioxide, the byproduct of metabolic functions carried out throughout the body. The heart supplies blood to the two circuits with pulses generated by the orderly muscular contraction of its walls.
In order to keep blood moving through these two separate circulatory circuits, the human heart has four distinct chambers that work in pairs. As illustrated in
In the systemic circuit, the other pair of chambers pumps the oxygenated blood through body organs, tissues and bones. The blood moves from the left atrium 16, where it flows from the lungs, to the left ventricle 18, which in turn pumps the blood throughout the body and all the way back to the right atrium 12. The blood then moves to the right ventricle 14 where the cycle is repeated. In each circuit, the blood enters the heart through an atrium and leaves the heart through a ventricle.
Thus, the ventricles 14,18 are essentially two separate pumps that work together to move the blood through the two circulatory circuits. Four check valves control the flow of blood within the heart and prevent flow in the wrong direction. A tricuspid valve 20 controls the blood flowing from the right atrium 12 into the right ventricle 14. Similarly, a bicuspid valve 22 controls the blood flowing from the left atrium 16 into the left ventricle 18. Two semilunar valves (pulmonary 24 and aortic 26) control the blood flow leaving the heart toward the pulmonary and systemic circuits, respectively. Thus, in each complete cycle, the blood is pumped by the right ventricle 14 through the pulmonary semilunar valve 24 to the lungs and back to the left atrium 16. The blood then flows through the bicuspid valve 22 to the left ventricle 18, which in turn pumps it through the aortic semilunar valve 26 throughout the body and back to the right atrium 12. Finally, the blood flows back to the right ventricle 14 through the tricuspid valve 20 and the cycle is repeated.
When the heart muscle squeezes each ventricle, it acts as a pump that exerts pressure on the blood, thereby pushing it out of the heart and through the body. The blood pressure, an indicator of heart function, is measured when the heart muscle contracts as well as when it relaxes. The so-called systolic pressure is the maximum pressure exerted by the blood on the arterial walls when the left ventricle of the heart contracts forcing blood through the arteries in the systemic circulatory circuit. The so-called diastolic pressure is the lowest pressure on the blood vessel walls when the left ventricle relaxes and refills with blood. Healthy blood pressure is considered to be about 120 millimeters of mercury systolic and 80 millimeters of mercury diastolic (usually presented as 120/80).
Inasmuch as the function of the circulatory system is to service the biological needs of all body tissues (i.e., to transport nutrients to the tissues, transport waste products away, distribute hormones from one part of the body to another, and, in general, to maintain an appropriate environment for optimal function and survival of tissue cells), the rate at which blood is circulated by the heart is a critical aspect of its function. The heart has a built-in mechanism (the so-called Frank-Starling mechanism) that allows it to pump automatically whatever amount of blood flows into it. Such cardiac output in a healthy human body may vary from about 4 to about 15 liters per minute (LPM), according to the activity being undertaken by the person, at a heart rate that can vary from about 50 to about 180 beats per minute.
Several artificial devices have been developed over the years to supplement or replace the function of a failing heart in a patient. Typically, these artificial devices consist of pumps that aim at duplicating the required pumping functions of the left and right human ventricles. Ventricular assist devices, normally referred to as VADs, are mechanical circulatory devices used to partially or completely replace the function of a failing heart. Some VADs are used for a short term in patients recovering from heart attacks or heart surgery, while others are used for months or even years in patients suffering from congestive heart failure.
In contrast to artificial hearts, which are designed to completely take over the cardiac function and generally require the removal of the patient's heart, VADs are designed to assist either the left or the right ventricle, or both. They are either implanted or connected externally between the left ventricle and the aorta or the right ventricle and the pulmonary artery, respectively. Left ventricle VADs are most commonly used, but right ventricular assistance may become necessary as well when pulmonary arterial resistance is high. Long-term VADs are normally used to keep patients alive with a good quality of life while they wait for a heart transplant. However, VADs are sometimes also used in therapeutic applications and as a bridge to recovery.
Most VADs utilize two valves connected to a pump. One valve controls the inflow to the pump chamber, while the other controls its outflow into the patient's circulatory system. Therefore, these valves are critical to the operation of the VAD and the survival of the patient. Over the years, these valves have consisted either of bioprostheses made of animal heart valves or tissue, or of mechanical valves made of plastic materials. Bioprostheses exhibit high biocompatibility but are not suitable for long-term applications because of their limited durability. Mechanical valves are durable but produce blood clotting (“thrombus”) because of the blood flowing over a non-biological surface. This is a recurring problem in the performance of VADs and anticoagulant compounds are typically used to reduce the risk of malfunction. However, clotting remains the most serious hurdle for the long-term use of mechanical VADS in patients.
The design of mechanical VAD valves has evolved over time with the dual objectives of improving durability, which of course is the most critical aspect of VADs' performance, and of minimizing thrombus. The geometry of the valve, in addition to the material, is believed to be most crucial for minimizing thrombus. Early ball-valve designs were replaced by valves with disk-shaped flaps sealing the circular passage in and out of the VAD. Various geometries have been implemented with one, two or three flaps hinged to a peripheral ring, but none has produced a satisfactory solution to the clotting problem. The relatively rough closing mechanisms and the dead-flow zones around the hinges of the flaps are the source of clotting in these valves. Therefore, the present invention involves a novel flap design directed at producing a smoother closing motion and at eliminating areas of blood accumulation within the valve, especially around the points of attachment of the flaps.
A major concern in designing an improved valve for ventricular assist devices is a configuration that reduces turbulence and promotes flow around all components of the valve so as to eliminate dead zones that increase the chance of clotting. To that end, according to one aspect of the invention, the new VAD valve includes multiple flaps, preferably two, hinged to a peripheral wall by means of a couple of flexible struts. As each flap opens and closes during each cycle of operation, the struts flex and open passages for flow around them, around the flaps, and between the struts and the flaps, so as to prevent the formation of dead zones that contribute to the accumulation and deterioration of blood cells that produce clotting.
According to another, very important, aspect of the invention, the struts are tensioned so as to exert a pressure against the flow of the blood stream when the flaps are open. This tension creates a pressure differential between the underside and the peripheral regions of the flaps that forces blood flow around the hinges and washes out any stagnant cells. As a result, clotting is reduced materially in comparison with prior-art valves.
Additional features and advantages of the invention will be forthcoming from the following detailed description of certain specific embodiments when read in conjunction with the accompanying drawings.
Referring to the figures, wherein the same reference numerals and symbols are used to refer to equal parts,
For ease of description, the terms up and down are used with reference to the figures in describing the function of the valve 30, it being understood that the actual position of the valve components and the direction of flow would in fact depend on the placement of the valve in the VAD. As seen in the top view of
As illustrated in the figures and well understood by one skilled in the art, the exact shape of the flaps 40 is not as crucial to the invention as the strut tensioning and the configuration of the strut attachment to the housing, so long as the struts are appropriately dimensioned to conform with and mesh well with each other and the seat of the valve to properly prevent back-flow in their closed position. As such, it is anticipated that the invention could be practiced with comparably advantageous results using three equal flaps, each designed to cover one third of the opening in the valve. The use of a single flap, while possible, would introduce undesirable flow asymmetries that could promote clotting and therefore it is not recommended. Similarly, a different number of struts could be used for each flap, though not recommended because a single strut might cause uneven flap motion and more than two struts would be an unnecessary complication.
The valve of the invention is currently being tested for marketing by SynCardia Systems, Inc., of Tucson, Ariz. The valve is injection-molded in several polyurethane parts (the housing, the struts and flaps, and the ring) that are then assembled and glued together into a single valve unit. While polyurethane is the preferred material, the valve could be made as well with other synthetic materials, such as silicone rubber, a thermoplastic elastomer (TPE), or polyvinyl chloride (PVC).
The SynCardia valve was tested in a conventional VAD, such as illustrated in
While the invention has been shown and described herein with reference to what is believed to be the most practical embodiment, it is recognized that departures can be made within the scope of the invention. For example, the struts of the invention may be attached to the housing with glue or be formed as a single structure. Therefore, the invention is not to be limited to the disclosed details, but is intended to embrace all equivalent structures and methods.